High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment

Documenti analoghi

• Impact of Dose‐Escalation Design on the Safety and Development of Anticancer Drugs in Clinical Trials
  di: Atsushi Nonami, et al.
  Pubblicazione: (2025)
• New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug
  di: Yusuke Okada, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
  di: Avner Sandhu, et al.
  Pubblicazione: (2025)
• First‐In‐Human Safety, Tolerability, and Pharmacokinetics of PPI‐1011, a Synthetic Plasmalogen Precursor
  di: Tara Smith, et al.
  Pubblicazione: (2025)
• First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
  di: Marcus May, et al.
  Pubblicazione: (2025)